Journal
CLINICAL EPIGENETICS
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13148-016-0186-5
Keywords
Telomere length; CpG methylation; Epigenetic age acceleration; Frailty index; Cross-sectional study; General population
Categories
Funding
- Baden Wurttemberg Ministry of Science, Research and Arts
- Federal Ministry of Education and Research
Ask authors/readers for more resources
Background: The epigenetic clock, in particular epigenetic pre-aging quantified by the so-called DNA methylation age acceleration, has recently been suggested to closely correlate with a variety of disease phenotypes. There remains a dearth of data, however, on its association with telomere length and frailty, which can be considered major correlates of age on the genomic and clinical level, respectively. Results: In this cross-sectional observational study on altogether 1820 subjects from two subsets (n = 969 and n = 851; mean +/- standard deviation age 62.1 +/- 6.5 and 63.0 +/- 6.7 years, respectively) of the ESTHER cohort study of the elderly general population in Germany, DNA methylation age was calculated based on a 353 loci predictor previously developed in a large meta-study, and the difference-based epigenetic age acceleration was calculated as predicted methylation age minus chronological age. No correlation of epigenetic age acceleration with telomere length was found in our study (p = 0.63). However, there was an association of DNA methylation age acceleration with a comprehensive frailty measure, such that the accumulated deficits significantly increased with increasing age acceleration. Quantitatively, about half an additional deficit was added per 6 years of methylation age acceleration (p = 0.0004). This association was independent from age, sex, and estimated leukocyte distribution, as well as from a variety of other confounding variables considered. Conclusions: The results of the present study suggest that epigenetic age acceleration is correlated with clinically relevant aging-related phenotypes through pathways unrelated to cellular senescence as assessed by telomere length. Innovative approaches like Mendelian randomization will be needed to elucidate whether epigenetic age acceleration indeed plays a causal role for the development of clinical phenotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available